Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 PURCHASE, N.Y., Oct. 01, 2024 ...
Add Yahoo as a preferred source to see more of our stories on Google. We all know about Alzheimer’s Disease, in fact, many of us know someone who has been impacted by it. But there is another form of ...
(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...
A type of Alzheimer’s drug appears to slow the progression of Lewy body dementia Cholinesterase inhibitors slowed progression of Lewy body dementia compared to another common Alzheimer’s med ...
A comprehensive study spanning a decade shed new light on the treatment of dementia with Lewy bodies (DLB), a condition that significantly impacts older adults. The research, published in Alzheimer’s ...
An estimated 10,000-12,000 people are living with Lewy body dementia in Ireland, but only a small number of sufferers get an accurate diagnosis ...
Editor’s Note: The following column was originally published May 28, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase ...
Nonprofit senior living operator FellowshipLife recently launched a new, voluntary genetic testing program for residents and their families aimed at ...
The MarketWatch News Department was not involved in the creation of this content. According to DelveInsight's analysis, the Lewy body dementia market is anticipated to increase during the forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results